PatientsVille.com Logo


Atralin Medical Research Studies

Up-to-date List of Atralin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Atralin Medical Research Studies

Rank Status Study
1 Recruiting Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: Tretinoin and Arsenic Trioxide
Outcome Measures: To determine the rate of molecular remission;   To determine the rate of clinical complete remission (CR) and the time to remission;   To determine the proportion of patients in molecular remission;   To determine the disease-free, event-free, and overall survival of patients;   To determine the toxicity of this treatment program;   To characterize the differentiation of APL cells during treatment;   Explore the in vivo induction of telomerase-dependent cell death
2 Recruiting Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: All-Trans Retinoic Acid (ATRA)
Outcome Measures: Maximum Tolerated Dose (MTD) of Lenalidomide/Dexamethasone and All-Trans Retinoic Acid (ATRA);   Objective Response
3 Unknown  A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne
Condition: Acne Vulgaris
Interventions: Drug: clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;   Drug: clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
Outcome Measures: Change in PGA scores of patients using combination clindamycin phosphate 1.2%/tretinoin 0.025% gel with or without benzoyl peroxide 6% foaming cloths for facial acne;   Change in Postinflammatory hyperpigmentation score at each study visit and from baseline to final visit.;   Total number of adverse events.;   Change in Subject Self Assessment Scoring Scale;   Change in Acne-Specific Quality of Life Questionnaire (Acne-QoL)
4 Recruiting Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: tretinoin;   Drug: lithium carbonate;   Other: laboratory biomarker analysis
Outcome Measure: Maximum tolerated dose of tretinoin when given together with lithium carbonate, defined as the dose level immediately below that at which at least 2/6 subjects experience dose-limiting toxicity (DLT), graded using the NCI CTCAE version 4.0
5 Recruiting A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging
Conditions: Photoaging;   Photodamage
Interventions: Drug: Adapalene;   Drug: Tretinoin
Outcome Measures: Assessing the extent of Cutaneous Photoaging at the end of treatment.;   Global Assessment of photoaging, based on the Griffiths photonumeric scale.;   Assessing the extent of Cutaneous Photoaging at each visit.;   Evaluation of Improvement by the Investigator at Week 12;   Evaluation of Improvement by the Investigator at Week 24;   Subject Assessment of improvement at week 24.;   Anatomical-pathological assessment;   Digital morphometric assessment.
6 Not yet recruiting RA-2 13-cis Retinoic Acid (Isotretinoin)
Conditions: Male Infertility;   Klinefelter's Syndrome;   Y-chromosome Microdeletions
Intervention: Drug: 13-cis retinoic acid
Outcome Measures: Total motile sperm;   13-cis retinoic acid serum level;   Number of Participants with Serious and Non-Serious Adverse effects associated with treatment with 13-cis retinoic acid;   13-cis retinoic acid Seminal Plasma Concentration
7 Recruiting All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Interventions: Drug: All-Trans Retinoid Acid(ATRA);   Drug: Dexamethasone
Outcome Measure: Platelet count
8 Recruiting Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: ATRA+arsenic;   Drug: ATRA+chemo
Outcome Measures: disease free survival;   overall survival
9 Recruiting Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: dasatinib (SPRYCEL);   Drug: all trans retinoic acid (VESANOID)
Outcome Measures: To determine the MTD and DLTs of dasatinib in combination with ATRA given the proposed dose escalation plan.;   Assessment of Differentiation. Bone marrow biopsies and aspirates will be obtained pre-treatment, on day 14, and day 28. These will be subjected to morphologic, cytochemical, and routine flow cytometric analyses.;   Assess treatment effects on SFK (Src family kinase) activation and expression of RARA target genes.;   PK parameters including peak concentration (Cmax),Tmax, Cmin, the area under the curve (AUC), volume of distribution, clearance terms, elimination rate constant, and elimination half-life (t1/2) will be analyzed.
10 Recruiting 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
Condition: Neuroblastoma
Intervention: Drug: 3F8 and 13-cis-retinoic acid
Outcome Measures: Assess the impact of high-dose 3F8/GM-CSF;   Apply real-time quantitative RT-PCR;   Monitor safety of the high-dose antibody treatment
11 Recruiting 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
Condition: Neuroblastoma
Intervention: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
Outcome Measures: Assess the impact of high-dose 3F8/GM-CSF on relapse-free survival;   Apply real-time quantitative RT-PCR to test the hypothesis that the minimal residual disease content of bone marrow;   Monitor safety of the high-dose antibody treatment
12 Unknown  Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: bexarotene;   Drug: capecitabine;   Drug: carboplatin;   Drug: cisplatin;   Drug: docetaxel;   Drug: tretinoin
Outcome Measures: Response rate as measured by RECIST criteria;   Time to progression;   Survival;   Patient-reported symptoms and side effects
13 Recruiting Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
Condition: Leukemia
Interventions: Drug: ATRA;   Drug: ATO;   Drug: GO (Gemtuzumab ozogamicin);   Drug: Methylprednisolone
Outcome Measure: Event Free Survival (EFS)
14 Recruiting Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Decitabine;   Drug: VPA;   Drug: ATRA
Outcome Measures: Objective best response rate (complete remission (CR) and partial remission (PR));   Overall best response rate (CR, PR and antileukemic effect (ALE));   progression-free survival (PFS);   overall survival (OS);   quality of life;   safety and toxicity
15 Recruiting Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation
Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: Cytarabine;   Drug: Etoposide;   Drug: All-trans retinoic acid (ATRA)
Outcome Measures: overall survival;   Rate of Complete remission;   cumulative incidence of relapse;   cumulative incidence of death in complete remission;   event-free survival;   Rate of early deaths (ED)/hypoplastic deaths (HD);   Type, frequency, severity, timing and relatedness of adverse events (AEs) and laboratory abnormalities observed during different treatment cycles;   Incidence of infection after each treatment cycle;   Duration of neutropenia after each treatment cycle;   Duration of thrombocytopenia after each treatment cycle;   Duration of hospitalization after each treatment cycle;   Quality of life
16 Recruiting 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
Condition: Neuroblastoma
Intervention: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic
Outcome Measures: Assess the activity of high-dose 3F8/GM-CSF;   Apply real-time quantitative RT-PCR;   Monitor safety of the high-dose antibody treatment
17 Unknown  Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker
Condition: Non Small Cell Lung Cancer
Interventions: Drug: atRA;   Drug: Placebo
Outcome Measures: Obtain a greater response rate to chemotherapy, and an increase in PFS and the GS of patients with advanced-stage NSCLC who receive cisplatin- and paclitaxel-based chemotherapy and a 45-mg/m2 daily dose of atRA.;   Demonstrate an acceptable toxicological profile of patients with advanced NSCLC who receive chemotherapy and a daily 45-mg/m2 dose of atRA.
18 Recruiting The Lipid Profile of the Skin Surface in Acne
Condition: Acne
Interventions: Drug: Tretinoin or Adapalene;   Drug: Isotretinoin
Outcome Measures: Skin lipid profile of acne and healthy patients;   Skin lipid profile of acne patients after treatment
19 Recruiting Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
Condition: Acute Myelogenous Leukemia
Intervention: Drug: Cytarabine, all-trans retinoic acid, valproic acid
Outcome Measures: Survival;   Disease stabilization;   Disease complications;   Side effects of therapy
20 Not yet recruiting Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Conditions: Neuroblastoma;   Neoplasm, Residual;   Effects of Immunotherapy
Intervention: Drug: Dinutuximab. Immunotherapy
Outcome Measures: Number of Participants with Serious and Non-Serious Adverse Events;   Relapse-free survival

These studies may lead to new treatments and are adding insight into Atralin etiology and treatment.

A major focus of Atralin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Atralin